At a glance
- Originator Dainippon Sumitomo Pharma
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glycine gated NMDA receptor antagonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Neurological disorders
Most Recent Events
- 10 Feb 2006 No development reported - Preclinical for Epilepsy in Japan (unspecified route)
- 10 Feb 2006 No development reported - Preclinical for Neurological disorders in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma